Dainippon Lays Out R&D Table Ahead Of Latuda Challenges
Focus On Novel Schizophrenia Candidate
Vant deal, discovery platforms help Japanese firm build out pipeline before it faces the first expiries for its top seller.
You may also be interested in...
A transatlantic initiative is screening a US library of 15,000 pharmacologically active compounds for anti-COVID-19 activity, using artificial intelligence technologies.
Scrip spoke with Sumitovant CEO Myrtle Potter about short- and long-term goals for the portfolio of five companies, including Myovant, Urovant and Enzyvant with potential near-term approvals.
Keeping Track: US FDA's Rejection Of First RMAT BLA Blemishes Otherwise Positive Week Of Non-Oncology News
The latest non-oncology drug development news and highlights from our US FDA Performance Tracker.